Consulting
Supporting Drug Development – Increasing Probability of Success
Nick Davies; Beth Lindsey; Ian Smart
Verta Life Sciences
PAO-03-23-CL-04Mar 24, 2023
Tumor Microenvironment
Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies
Gil Efron
Purple Biotech
PAO-03-23-CL-01Mar 21, 2023
Bone Regeneration
A Novel Technology Platform for Bone Regeneration and Cancer Treatment
Denis Dufrane, M.D., Ph.D.
PAO-03-23-CL-06Mar 20, 2023
Point of Care
Helping Clinicians Make Better Decisions More Easily
Matt Titus
epocrates
PAO-03-23-CL-05Mar 16, 2023
Viral Vector Manufacturing
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Chris Berger; Kilian Witzel
Avid Bioservices
PAO-02-23-CL-03Mar 14, 2023
Digital Twin Technology
The Powerful Potential of Digital Twin Technology to Improve Drug Discovery, Development, Manufacturing, and More
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-23-NI-02Mar 07, 2023
FDA New Drug Approvals
Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-23-NI-03Mar 07, 2023
Interchangeable Biosimilars
The Opportunities and Challenges Posed by Biosimilar Interchangeability
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-23-NI-01Mar 07, 2023
Scale-Up
Scale-Up Expertise to Support Your Biologics Life Cycle
Pramthesh (Prem) Patel, Ph.D.
Avid Bioservices
PAO-02-23-CL-06Mar 02, 2023
Bioprinting
The Right Materials for Success in Bioprinting
Elena Meurer; Mariya Gromova
Biopharma Excellence
PAO-02-23-CL-05Feb 15, 2023
Clinical Trials
Early Reports of Positive Experiences with EMA’s New Clinical Trials Information System
Kieran O’Donnell; Nicola Kidman
PAO-02-23-CL-02Feb 15, 2023
Lipid Nanoparticles
Lipid Nanoparticles: Transforming the Nanomedicines Market
Antonio Costa, Ph.D.
DIANT Pharma
PAO-02-23-CL-01Feb 07, 2023
Antibody Production
From Llamas to Yeast: Producing Functional Therapeutic Antibody Fragments in Saccharomyces cerevisiae
Phenotypeca
PAO-01-23-CL-05-153Feb 01, 2023
Gene Tools
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
David Alvaro, Ph.D.; Jon Moulton, Ph.D.
Pharma's Almanac
PAO-01-23-CL-05Feb 01, 2023
Cell Therapy
Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-01-23-NI-01Jan 31, 2023
Anti-Idiotype Antibodies
Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development
Na Li, Ph.D.
Sino Biological
PAO-01-23-CL-01Jan 13, 2023